KDR and neoplasm: Targeting tumour stromal cells with fibroblast activation protein (FAP)‐directed CAR‐T cells to inhibit matrix production and angiogenesis87Directing CAR‐T cell to target vascular endothelial growth factor receptor 2(VEGFR2)88Engineering CAR‐T cells to secrete extracellular matrix (ECM)‐modifying enzymes heparanase89